Advertisement

Langenbeck's Archives of Surgery

, Volume 400, Issue 6, pp 715–723 | Cite as

Palliative resection of the primary tumor in 442 metastasized neuroendocrine tumors of the pancreas: a population-based, propensity score-matched survival analysis

  • Felix J. Hüttner
  • Lutz Schneider
  • Ignazio Tarantino
  • Rene Warschkow
  • Bruno M. Schmied
  • Thilo Hackert
  • Markus K. Diener
  • Markus W. Büchler
  • Alexis Ulrich
Original Article

Abstract

Purpose

There is an ongoing debate on whether palliative removal of the primary tumor may result in a survival benefit for patients with incurable stage IV pancreatic neuroendocrine tumors (P-NET). The objective of this study was to assess whether palliative resection of the primary tumor in patients with incurable stage IV P-NET has an impact on survival.

Methods

Patients with stage IV P-NET registered in the Surveillance, Epidemiology, and End Results database between 2004 and 2011 were identified. Those undergoing resection of metastases were excluded. Overall and cancer-specific survival of patients who did and did not undergo resection of their primary tumor were compared by means of risk-adjusted Cox proportional hazard regression analysis and propensity score-matched analysis.

Results

A total of 442 stage IV P-NET patients were identified, of whom 75 (17.0 %) underwent palliative primary tumor resection. The latter showed a significant benefit in both overall survival (hazard ratio [HR] of death = 0.41, 95 % confidence interval [CI] 0.25–0.66, p < 0.001) and cancer-specific survival (HR of death = 0.41, 95 % CI 0.25–0.67, p < 0.001) in unadjusted multivariate Cox regression analysis; the benefit persisted after propensity score adjustment.

Conclusions

This population-based analysis of stage IV P-NET patients provides compelling evidence that palliative resection of the primary tumor is associated with significant survival benefit. Thus, the recent recommendations judging resection of the primary as inadvisable and the accompanying trend towards fewer palliative resections of the primary tumor have to be contested.

Keywords

Pancreatic neuroendocrine tumors Metastases Primary tumor resection Palliative Survival 

Notes

Acknowledgments

The authors thank the National Cancer Institute for providing the SEER registry data.

Funding

No funding was received for this study.

Conflicts of interest

The authors declare that no conflicts of interest exist in relation to this study.

Ethical approval

All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Since the data source for this retrospective study was the SEER database of the National Cancer Institute of the United States of America, no formal consent is required for this type of study.

References

  1. 1.
    Fitzgerald TL, Hickner ZJ, Schmitz M, Kort EJ (2008) Changing incidence of pancreatic neoplasms: a 16-year review of statewide tumor registry. Pancreas 37(2):134–138CrossRefPubMedGoogle Scholar
  2. 2.
    Modlin IM, Champaneria MC, Chan AK, Kidd M (2007) A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress. Am J Gastroenterol 102(7):1464–1473CrossRefPubMedGoogle Scholar
  3. 3.
    Vagefi PA, Razo O, Deshpande V, McGrath DJ, Lauwers GY, Thayer SP, Warshaw AL, Fernandez-Del CC (2007) Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005. Arch Surg 142(4):347–354PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063–3072CrossRefPubMedGoogle Scholar
  5. 5.
    Halfdanarson TR, Rabe KG, Rubin J, Petersen GM (2008) Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 19(10):1727–1733PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Metz DC, Jensen RT (2008) Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 135(5):1469–1492PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, Blumgart LH (2000) Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190(4):432–445CrossRefPubMedGoogle Scholar
  8. 8.
    Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA (1998) Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 187(1):88–92, discussion 92–3 CrossRefPubMedGoogle Scholar
  9. 9.
    House MG, Cameron JL, Lillemoe KD, Schulick RD, Choti MA, Hansel DE, Hruban RH, Maitra A, Yeo CJ (2006) Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer. J Gastrointest Surg 10(1):138–145CrossRefPubMedGoogle Scholar
  10. 10.
    Sarmiento JM, Que FG, Grant CS, Thompson GB, Farnell MB, Nagorney DM (2002) Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach. Surgery 132(6):976–982, discussion 982–3 CrossRefPubMedGoogle Scholar
  11. 11.
    Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197(1):29–37CrossRefPubMedGoogle Scholar
  12. 12.
    Bruzoni M, Parikh P, Celis R, Are C, Ly QP, Meza JL, Sasson AR (2009) Management of the primary tumor in patients with metastatic pancreatic neuroendocrine tumor: a contemporary single-institution review. Am J Surg 197(3):376–381CrossRefPubMedGoogle Scholar
  13. 13.
    Capurso G, Bettini R, Rinzivillo M, Boninsegna L, Delle FG, Falconi M (2011) Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: a systematic review. Neuroendocrinology 93(4):223–229CrossRefPubMedGoogle Scholar
  14. 14.
    Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF, Tseng JF (2009) Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer 115(4):741–751CrossRefPubMedGoogle Scholar
  15. 15.
    Falconi M, Bartsch DK, Eriksson B, Kloppel G, Lopes JM, O’Connor JM, Salazar R, Taal BG, Vullierme MP, O’Toole D, Barcelona Consensus Conference, Barcelona Consensus Conference p (2012) ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 95(2):120–134CrossRefPubMedGoogle Scholar
  16. 16.
    Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, Scoazec JY, Salazar R, Sauvanet A, Kianmanesh R, Barcelona Consensus Conference p (2012) ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 95(2):98–119PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Smith JK, Ng SC, Hill JS, Simons JP, Arous EJ, Shah SA, Tseng JF, McDade TP (2010) Complications after pancreatectomy for neuroendocrine tumors: a national study. J Surg Res 163(1):63–68CrossRefPubMedGoogle Scholar
  18. 18.
    Bettini R, Mantovani W, Boninsegna L, Crippa S, Capelli P, Bassi C, Scarpa A, Pederzoli P, Falconi M (2009) Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. Dig Liver Dis 41(1):49–55CrossRefPubMedGoogle Scholar
  19. 19.
    Wingo PA, Jamison PM, Hiatt RA, Weir HK, Gargiullo PM, Hutton M, Lee NC, Hall HI (2003) Building the infrastructure for nationwide cancer surveillance and control—a comparison between the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) Program (United States). Cancer Causes Control 14(2):175–193CrossRefPubMedGoogle Scholar
  20. 20.
    Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S (2000) International Classification of Disease for Oncology, 3rd edn. World Health Organization, Geneva, SwitzerlandGoogle Scholar
  21. 21.
    Rubin DB (1997) Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127(8 Pt 2):757–763CrossRefPubMedGoogle Scholar
  22. 22.
    Joffe MM, Rosenbaum PR (1999) Invited commentary: propensity scores. Am J Epidemiol 150(4):327–333CrossRefPubMedGoogle Scholar
  23. 23.
    Rosenbaum PR (1987) Model-based direct adjustment. J Am Stat Assoc 82:387–394CrossRefGoogle Scholar
  24. 24.
    Hansen BB, Klopfer SO (2006) Optimal full matching and related designs via network flows. J Comput Graph Statist 15:609–627CrossRefGoogle Scholar
  25. 25.
    Rosche M, Regierer AC, Schwarzlose-Schwarck S, Weigel A, Bangemann N, Schefe JH, Scholz CW, Possinger K, Eucker J (2011) Primary tumor excision in stage IV breast cancer at diagnosis without influence on survival: a retrospective analysis and review of the literature. Onkologie 34(11):607–612CrossRefPubMedGoogle Scholar
  26. 26.
    Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, Kwekkeboom D, Lau WY, Klersy C, Vilgrain V, Davidson B, Siegler M, Caplin M, Solcia E, Schilsky R, Working Group on Neuroendocrine Liver M (2014) Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 15(1):e8–e21CrossRefPubMedGoogle Scholar
  27. 27.
    Nguyen SQ, Angel LP, Divino CM, Schluender S, Warner RR (2007) Surgery in malignant pancreatic neuroendocrine tumors. J Surg Oncol 96(5):397–403CrossRefPubMedGoogle Scholar
  28. 28.
    Solorzano CC, Lee JE, Pisters PW, Vauthey JN, Ayers GD, Jean ME, Gagel RF, Ajani JA, Wolff RA, Evans DB (2001) Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 130(6):1078–1085CrossRefPubMedGoogle Scholar
  29. 29.
    Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K, Rad001 in Advanced Neuroendocrine Tumors T.T.S.G. (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514–523PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364(6):501–513CrossRefPubMedGoogle Scholar
  31. 31.
    Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, Macke HR, Rochlitz C, Muller-Brand J, Walter MA (2011) Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 29(17):2416–2423CrossRefPubMedGoogle Scholar
  32. 32.
    Villard L, Romer A, Marincek N, Brunner P, Koller MT, Schindler C, Ng QK, Macke HR, Muller-Brand J, Rochlitz C, Briel M, Walter MA (2012) Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol 30(10):1100–1106CrossRefPubMedGoogle Scholar
  33. 33.
    Vogl TJ, Naguib NN, Zangos S, Eichler K, Hedayati A, Nour-Eldin NE (2009) Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol 72(3):517–528CrossRefPubMedGoogle Scholar
  34. 34.
    Gedaly R, Daily MF, Davenport D, McHugh PP, Koch A, Angulo P, Hundley JC (2011) Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg 146(8):953–958CrossRefPubMedGoogle Scholar
  35. 35.
    Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA Jr, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N (2011) DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331(6021):1199–1203PubMedCentralCrossRefPubMedGoogle Scholar
  36. 36.
    McPhee JT, Hill JS, Whalen GF, Zayaruzny M, Litwin DE, Sullivan ME, Anderson FA, Tseng JF (2007) Perioperative mortality for pancreatectomy: a national perspective. Ann Surg 246(2):246–253PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    Buchler MW, Wagner M, Schmied BM, Uhl W, Friess H, Z’Graggen K (2003) Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy. Arch Surg 138(12):1310–1314, discussion 1315 CrossRefPubMedGoogle Scholar
  38. 38.
    Gouma DJ, van Geenen RC, van Gulik TM, de Haan RJ, de Wit LT, Busch OR, Obertop H (2000) Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann Surg 232(6):786–795PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Felix J. Hüttner
    • 1
    • 2
  • Lutz Schneider
    • 1
  • Ignazio Tarantino
    • 1
  • Rene Warschkow
    • 3
    • 4
  • Bruno M. Schmied
    • 3
  • Thilo Hackert
    • 1
  • Markus K. Diener
    • 1
    • 2
  • Markus W. Büchler
    • 1
  • Alexis Ulrich
    • 1
  1. 1.Department of General, Visceral, and Transplant SurgeryUniversity of HeidelbergHeidelbergGermany
  2. 2.Study Center of the German Surgical SocietyUniversity of HeidelbergHeidelbergGermany
  3. 3.Department of SurgeryKantonsspital St. GallenSt. GallenSwitzerland
  4. 4.Institute of Medical Biometry and InformaticsUniversity of HeidelbergHeidelbergGermany

Personalised recommendations